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Complement activation is needed to restore tissue injury; however, inappropriate activation of complement, as seen in chronic
wounds can cause cell death and enhance inflammation, thus contributing to further injury and impaired wound healing.
Therefore, attenuation of complement activation by specific inhibitors is considered as an innovative wound care strategy.
Currently, the eﬀects of several complement inhibitors, for example, the C3 inhibitor compstatin and several C1 and C5 inhibitors,
are under investigation in patients with complement-mediated diseases. Although (pre)clinical research into the eﬀects of these
complement inhibitors on wound healing is limited, available data indicate that reduction of complement activation can improve
wound healing. Moreover, medicine may take advantage of safe and eﬀective agents that are produced by various microorganisms,
symbionts, for example, medicinal maggots, and plants to attenuate complement activation. To conclude, for the development
of new wound care strategies, (pre)clinical studies into the roles of complement and the eﬀects of application of complement
inhibitors in wound healing are required.
1. Introduction
1.1. Wound Healing. Wound healing is often completed
within two weeks after injury, although tissue remodeling
may take several months up to two years. The process of
wound healing consists of three, overlapping phases, that is,
inflammation, tissue proliferation and tissue remodeling [1–
3]. During the diﬀerent phases, a complex series of sequential
cellular and biochemical responses, which are described in
some detail in Section 1.2, restores the injured tissue.
Chronic wounds occur in individuals having defects
that either prevent the healing process or allow healing
to continue without leading to a proper anatomical and
functional result. Risk factors for the development of chronic
wounds include vascular diseases, diabetes mellitus, pressure
(necrosis), alcohol and nicotins abuse, and old age [2].
Current therapies for chronic wounds include debridement,
reduction of bacterial load, pressure oﬄoading, topical
negative pressure, a variety of wound dressings, skin grafting,
and reconstructive tissue flaps [4, 5]. However, the outcome
of these therapies is unsatisfactory in up to 50% of chronic
(present for one year) wounds [6], resulting in significant
morbidity and mortality to patients. Development of new
therapies that promote the healing of chronic wounds is
therefore an important area of current research. A potential
new treatment could be cellular therapy with bone marrow-
derived mesenchymal stem cells [6, 7]. Other promis-
ing strategies involve the application of anti-inflammatory
agents, for example, complement inhibitors, as persistent
inflammation is often key to impaired wound healing [2, 8,
9].
1.2. Cellular and Molecular Processes Restore Injured Tissues.
Tissue injury immediately initiates an array of physiological
processes that lead to wound repair and regeneration.
Although the exact underlying mechanisms of action are
unclear, it is known that the immune systems play an
essential role in the regulation of these processes [1–3].
Instantly after tissue injury, damage-associated molecules,
such as S100 and the high mobility group box 1 (HBGM1)
proteins, defensins, lectins, cardiolipin, cellular DNA and
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dsRNA, and even intact mitochondria, occur in the extracel-
lular microenvironment. Interaction of these molecules with
multiligand receptors, such as toll-like receptors (TLRs) and
C-type lectins, on surfaces of tissue and immune cells activate
the cellular and molecular eﬀector mechanisms of the innate
immune system, including activation of the clotting and
complement system, acute phase protein and pentraxin
production, and the cellular inflammatory responses [10].
Following blood capillary vessel injury, an immediate
reflex promotes vasoconstriction, slowdown of blood flow,
and the local formation of a platelet clot. In addition, injured
tissue cells release factors that stimulate the formation of
a fibrin clot (containing a.o. fibronectin and vitronectin),
that traps blood cells including platelets and red blood cells.
This provisional extracellular matrix allows tissue cells to
migrate to the wound area. The activated kallikrein-kinin
system provides vasoactive kinins that mediate vasodilation
and increased vascular permeability. The complement system
is activated by distinct carbohydrate and lipid residues on
altered self-molecules and injured cells and the cellular
inflammatory response is subsequently initiated. Neutrophils
are the first inflammatory cells that migrate into wounds to
debride necrotic and apoptotic cells and eliminate infectious
agents from the wound bed [3]. Gradually neutrophils
are replaced by monocytes that exert the same scavenging
activities. Monocytes at the wound site will also develop
into macrophages that produce an array of inflammatory
molecules, including chemokines, anti-inflammatorymedia-
tors, enzymes (proteolytic enzymes, metalloproteases), reac-
tive oxygen species, and growth factors. A major drawback
of infiltration of activated phagocytes is their ability to
produce and release reactive oxygen species and proteolytic
proteases that exert detrimental eﬀects on healthy tissue cells
[3]. In addition, immature dendritic cells collect antigens,
for example, altered self-antigens, at the site of the wound
and transport them to the draining lymph nodes where the
dendritic cells mature and instruct T cells become eﬀector
cells.
The chemotactic mediators and growth factors pro-
duced by macrophages and healthy bystander cells stimulate
angiogenesis and attract endothelial cells and fibroblasts
that contribute to the proliferative phase of wound healing
[3]. Simultaneously, eﬀector T lymphocytes migrate to
the wound and play a regulatory role in wound healing
and collagen levels [3]. During the remodeling phase of
the healing process, redundant cells die by apoptosis and
collagen is remodeled and realigned. While the functions
of the cells involved in the healing processes have been
reported in much more detail than that described above, the
biochemical responses leading to the activation of these cells
at the site of injury are not widely investigated. However,
it is well known that activation of the complement system
is crucial in regulating the cellular responses in innate
immunity.
1.3. Aims of This Paper. As described above, the first response
to tissue injury is characterized by activation of the cellular
and molecular eﬀectors of the innate immune system,
including the complement system. However, inappropriate
complement activation, for example, in chronic wounds, will
result in detrimental eﬀects due to its ability to induce cell
death and promote prolonged inflammation [10, 11]. Exper-
iments in animals with deficiencies in complement com-
ponents indicate that attenuation of complement activation
promotes wound healing [12–19]. Therefore, complement
inhibitors are considered as candidates for development of
novel therapeutic agents for chronic nonhealing wounds.
Based on these considerations, this paper focuses on (1)
the current understanding of the dual roles of complement
activation in wound healing and (2) the present and novel
complement inhibitors to be considered for treatment of
chronic wounds.
2. Overview of the Complement Pathways and
Their Functions in Wounds
2.1. The Complement System. The activated complement
system is a crucial eﬀector mechanism of the innate immune
response to tissue injury. In general, the complement system
can be activated by a number of pathways: the classical
pathway (by immune complexes), the lectin pathway (by
mannose residues and ficolins), and the alternative pathway
(by spontaneous activation and microbial structures) and by
properdin and thrombin [20]. The result of activation of any
of these pathways is cleavage of the central factor C3 into C3a
and C3b by C3 convertase (except thrombin, which activates
the cleavage of C5 by C5 convertase) [21]. Thereafter, the
terminal pathway of the complement system with factors
C5b to C9 is completed (Figure 1). These latter factors
form the membrane attack complex (MAC), which creates
pores in the microbial cell wall resulting in cell lysis. C3a
and C5a are the most important chemoattractants that are
produced as part of the activation of the complement system.
In addition, recognition of necrotic and apoptotic cells by
activated complement components leads to the deposition
of complement components, such as C3-fragments, on their
membrane, which promotes phagocytosis and elimination of
the damaged cells by phagocytic cells and also results in the
generation of the MAC on these damaged cells. The major
drawback of complement activation is that the tolerance
against self-molecules can be broken, leading to responses to
these self-molecules and, as a consequence, to further tissue
injury and impairment of wound healing (Figure 1). Fortu-
nately, host cells are protected from complement-mediated
injury by fluid phase and membrane-bound regulators of
complement activation, such as factor B, factor D, factor I,
CD35, CD46, CD55, and CD59 [22, 23]. However, during
tissue injury, the expression of these complement regulators
may be decreased, resulting in reduced protection of the cells
and increased tissue damage. Together, while complement
activation is needed to restore tissue injury, inappropriate
complement activation can cause injury and contribute to
further tissue damage [11].
2.2. Roles of Complement in Wound Healing. There are a
few studies that report beneficial eﬀects of complement-
activating components on wound healing. First, Strey et al.
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Figure 1: A simplified overview of the complement activation cascade after injury leading to wound healing. Three major pathways of
complement activation, that is, the classical pathway (CP), the alternative pathway (LP), and the lectin pathway (LP), and two minor
pathways initiated by properdin and thrombin are known. C is a complement component, MASP is mannan-binding serine peptidase,
fB and D are factors B and D, SCIN is staphylococcal complement inhibitor, sCR1 is soluble complement receptor 1, fH is factor H, CR2 is
complement receptor 2 and MAC is membrane attack complex. For simplicity, not all of the natural regulators of complement activation are
shown in this diagram. The (pre)clinical complement inhibitors are denoted in bold and the complement factors that have been investigated
in burn wound models in italic. C1 inhibitor aﬀects C1r, C1s from the CP, and MASP 1 and MASP 2 from the LP. C4 knockout also aﬀects
both CP and LP.
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reported that complement C3a and C5a are absolutely
required for liver repair in a mouse model of liver injury
[24]. Second, Bossi et al. topically applied C1q, vascular
endothelial growth factor, or saline on wounds in rats and
after 2 weeks vessel formation was examined [25]. Results
revealed that animals treated with C1q and vascular endothe-
lial growth factor exhibited increased numbers of new vessels
as compared to control animals. In addition, application
of C1q resulted in increased permeability, proliferation,
and chemotaxis of endothelial cells, indicating that C1q
has proangiogenic activity and thus can promote wound
healing [25]. Third, topical application of C3 (100 nM)
on a rat wound model resulted in a 74% increase in
maximum wound strength as compared to control rats [26].
Also, inflammatory cells, fibroblast migration and collagen
deposition in the wounds were enhanced in the C3-treated
mice as compared to control animals. Despite the positive
eﬀects of C1q or C3 application on wound healing in these
models of acute injury, the possibility that complement
components exert an entirely diﬀerent, that is, detrimental,
eﬀect on chronic wounds is likely. In agreement, in the
majority of chronic wounds, MAC deposition is found at the
ulcer margin, but not in the intact skin [27]. It has also been
shown that patients with chronic leg ulcers have increased
serum levels of C3 [28, 29].
While enhanced levels of complement activating factors
are found in chronic wounds, it is interesting to study
the outcomes of wounds in which complement activation
is attenuated. It has been shown that animals with a
genetic complement deficiency or individuals treated with
a complement inhibitor are protected from the symptoms
resulting from chronic inflammatory processes [12–17].
Interestingly, Wahl et al. published a study regarding the
eﬀect of complement depletion by cobra venom factor (CVF)
on healing of acute wounds in guinea pigs [13]. CVF forms
a stable complex with Bb resulting in continuously activated
C3/C5 convertase [14], resulting in depletion of complement
activity, while it is resistant to complement regulatory
factors, such as factor H and I. CVF was administered
intraperitoneally to guinea pigs over a 24-hour period while
control animals received the diluent of CVF. After 24 hours,
the wound exudates from the complement-depleted pigs
showed a 50% reduction in infiltrating neutrophils and four
times more erythrocytes than exudates from control animals.
Wound debridement, fibroblast proliferation, connective
tissue formation, and capillary regeneration did not diﬀer
between CVF-treated and control, wounded animals. It
should be realized that only acute wound healing was
investigated and that CVF could have had other systemic
eﬀects that aﬀected wound healing in the guinea pigs.
In this connection, it has been described that additional
injections of CVF were administered and that these guinea
pigs developed lethargy, leucopenia, and loss of weight.
Unfortunately, no definitive conclusion as to the role of
complement in wound healing can be drawn from these
data. Furthermore, CVF initially is a complement activator,
which can induce tissue damage instead of repair. Together,
complement components play opposite roles in acute and
chronic wounds.
2.3. Roles of Complement in Burn Wounds. Studies by Van de
Goot et al. into the roles of complement in burn wounds
showed enhanced levels of complement degradation factor
C3d, indicative of complement activation, in the wound
[30]. C3d remains elevated in the wound until 46 days
after the burn injury. The amount of the acute phase
reactant C-reactive protein and the influx of neutrophils and
macrophages were also higher in the wounds during this
period and indicate the persisting inflammation. Machens
et al. compared the amount of C3a in wound fluids from a
group of patients younger than 60 years and from a group
older than 60 years with deep second-degree burn wounds
[31]. Results revealed elevated C3a levels in both groups
during the first 24 hours after thermal injury. However,
thereafter the C3a levels in the wound fluid decreased in
the young group, but not in the group with the older
patients, indicating that persistent complement activation
is associated with the delayed wound healing in the older
patients. In agreement, others reported elevated serum levels
of C3 and C3d in patients with burn wounds and these
levels correlated with the severity of the trauma and the
clinical outcome [32]. Furthermore, Mulligan et al. found
that intravenous injection of soluble human recombinant
complement receptor type 1 (sCR1) at 5 and 15 minutes and
at 1 and 4 hours after thermal injury into rats resulted in
decreased dermal vascular permeability and water content
and reduced recruitment and activation of neutrophils in
wound biopsies as compared to the biopsies from control
rats [15]. The sCR1-treated rats were protected against
complement-dependent tissue injury. In another study,
the eﬀects of a C1 inhibitor intravenously administrated
immediately after thermal injury on progression of the
depth of fresh burn wounds in pigs were assessed [16]. In
contrast to the control group, the lower dermal vascular
network was not altered in the C1 inhibitor treatment group
and there was only activation of endothelial cells in the
subepidermal and mid-dermal layer. Whereas in the control
group there was necrosis of the lower dermal zones, these
zones were normal in the C1 inhibitor group. As most
studies focused on the short-term eﬀects of complement
inhibitors on wound healing, Begieneman et al. determined
the eﬀects of 14 daily intravenous administrations of C1
esterase inhibitor on wound progression in dorsal full-
thickness burn wounds in rats [17]. Results revealed that
the C1 inhibitor reduced the amount of granulation tissue
and macrophage infiltration in these animals. The amounts
of complement factors C3 and C4 in the wounds were
lower (although not significant) in the C1 inhibitor-treated
group than in the control group. Furthermore, the C1
inhibitor did enhance reepithelialization. The data from this
study show that systemic administration with C1 inhibitor
improves healing in burn wounds. In addition, Radke et al.
demonstrated in a pig burn wound model that inhibition
of C1 is beneficial for the clinical outcome, as indicated by
vital signs and reduced edema formation, and C1 inhibitor
diminished bacterial translocation [33]. Finally, Suber et al.
found reduced burn wound depth and neutrophil migration
in C4 knockout mice as compared to wild type animals
[18]. Burn wounds in C4-deficient mice healed without
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contracture, scar formation, or hair loss in contrast to
the wild type mice. Moreover, the severity of the burn
wound was significantly less in C4 knockout mice than in
wild type animals. Together, both in preclinical and animal
studies, attenuation of complement activation stimulates
the wound healing process. Therefore, the various potential
complement-inhibiting agents and their therapeutic eﬀects
are discussed in the next section.
3. Exogenous Complement Inhibitors
3.1. Current (Pre)Clinical Complement Inhibitors. In clinical
practice, only a few complement inhibitors are currently
available (Table 1). Plasma-derived human C1 inhibitors
berinert P and cinryze and the recombinant human C1
inhibitor conestat alfa are currently applied in patients
suﬀering from hereditary angioedema (HAE) [34, 35]. Fur-
thermore, C5 inhibitor eculizumab is used in patients with
paroxysmal nocturnal hematuria (PNH) [36]. An overview
of these and other (pre)clinical complement inhibitors and
their interaction with the complement system is given in
Table 1 and Figure 1.
Recently, the C5 inhibitor pexelizumab failed in a Phase
III study as it did not reduce infarction and mortality
in patients after coronary intervention [37]. Pexelizumab
inhibited both C5a and MAC formation in vitro, while
in vivo only C5a was reduced with minimal eﬀects on
inflammation and risk biomarkers. Compstatin (POT-4),
isolated from a phage-displayed random peptide library, is
the only C3 inhibitor under investigation in Phase II studies
for the treatment of acute macular degeneration (AMD)
[38]. Compstatin is also tested in preclinical experiments for
possible applications in PNH, sepsis, transplantation, and
cancer. Furthermore, Mirococept (APT070), a membrane-
targeted myristoylated peptidyl construct derived from sol-
uble complement receptor 1, is currently examined in a
multicenter, double-blind, randomized, case-control study
for prevention of ischemia-reperfusion injury in cadaveric
kidneys for transplantations [39, 40]. Anticomplement factor
D is analyzed in a Phase II study in patients with AMD [36].
However, the Phase II study with C5a-inhibitor PMX-53 in
AMD patients was discontinued because of lack of success.
Nevertheless, this inhibitor is still under investigation for the
use in osteoarthritis.
Phase I studies are performed with targeted factor H
(TT30), that is, factor H coupled to CR2, for AMD and
PNH [41]. This targeted inhibitor binds to C3b/C3d coated
cells and blocks assembly of C3 and C5 convertases. Various
other complement inhibitors coupled to CR2 were tested in
patients with chronic glomerulonephritis [42]. In addition,
the C5 inhibitor eculizumab, which is already approved by
the FDA for PNH, was also tested as treatment for several
other diseases, including kidney transplants and haemolytic
uraemic syndrome (HUS) [36]. The anti-C5 aptamer ARC
1905 is investigated for its potential use in AMD [36]. Finally,
the eﬀects of plasma-derived factor H concentrate, anti-
complement factor B (TA106) and C5 inhibitors, such as
mubodina and ergidina, in complement-mediated diseases
were evaluated in preclinical studies [36].
3.2. Medicinal Maggots Produce Complement Inhibitors. Lar-
vae of medicinal maggots (Lucilia sericata) are successfully
used to heal severe, infected acute and chronic wounds
in the clinical practice [43–46], and in 2004, Maggot
Debridement Therapy (MDT) was approved by the US Food
and Drug Administration (510[k] no. 33391) [47]. Our
current research focuses on the mechanisms underlying the
beneficial actions of maggots on wound healing. So far, mag-
got excretions/secretions (ES) in therapeutic concentration
ranges lack direct antibacterial properties [48] but inhibit
biofilm formation and multiple proinflammatory responses
[49, 50], which could explain part of the mechanism of
action of maggots in wound healing. Others reported bene-
ficial eﬀects of maggot ES on the modulation of extracellular
matrix components leading to enhanced tissue formation
and accelerated healing [51, 52].
Recently, we found that maggot ES eﬃciently reduced
complement activation in normal and immune-activated
sera in a dose-dependent fashion with maximal inhibition
of 99.9% (Figure 2) [53]. Most likely, ES degrade individual
complement components, at least C3 and C4, in a cation-
independent manner. Consumption of complement compo-
nents via ES-mediated initiation of the complement cascade
has been ruled out. The complement inhibitory molecule(s)
in maggot ES proved to be temperature- and protease-
resistant. Together, attenuation of complement activation by
ES may contribute to the improved wound healing that is
observed during MDT in the clinical practice [43–46]. As
maggots and their ES are well tolerated by patients, it can be
envisaged that the complement inhibitory molecules within
ES are potential candidates for the development of novel
complement inhibitors.
3.3. Complement Inhibitors Produced by Other Symbionts.
As the complement system is a rapid and eﬀective defense
system, practically each successful microorganism has devel-
oped strategies and molecules to evade the actions of
complement [54, 55]. Therefore, it is virtually impossible to
give a brief, complete overview of all complement inhibitors
produced by infectious agents described in the literature, but
we will show some examples. Staphylococcus aureus is one of
the pathogens that produces at least seven molecules with
complement inhibitory molecules, including C3 inhibit-
ing molecule staphylococcal complement inhibitor (SCIN),
which prevents the conversion of C3 by convertases (C3b/Bb
and C4b2a) and staphylococcal superantigen-like protein
7 that prevents C5 cleavage [54, 56]. Another example
pertains to the herring worm Anisakis simplex [57]. Con-
sumption of raw herring can cause intestinal infections by
this herring worm, which possesses complement-inhibiting
properties to evade the human immune defense. Anisakis
simplex also excretes biochemical substances that harm the
intestines. Therefore, the human immune system evolution-
ary developed (undefined) strategies against this parasitic
infection resulting in death of the herring worm in all
immunocompetent patients. Borreliaespecies, causing bor-
reliosis (Lyme disease), also produce complement inhibitors
to evade the innate immune system [58, 59]. Binding of
a borrelial surface protein to complement factor H limits
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Table 1: An overview of (pre)clinical complement inhibitors.
Complement inhibitor Medicine Diseases Study phase
Recombinant C1 inhibitor
Conestat alfa HAE
Side eﬀects: headache and allergy.
In clinical use, EU
approved.(Ruconest in Europe/Rhucin in
USA)
Plasma-derived C1 inhibitors Berinert P/cinryze HAE
In clinical use, FDA
approved.
C3 inhibitors
Compstatin (POT-4) AMD Phase II
Staphylococcal complement
inhibitor (SCIN)
Preclinical
Myristoylated peptidyl derived
from soluble CR1
Mirococept (APT070)
Delayed graft function of cadaveric
kidney after transplantation.
Phase II
Factor H
Plasma-derived factor H
concentrate
HUS, AMD Preclinical
TT30/targeted alternative
pathway inhibitor/factor H
PNH, AMD Phase I
Factor D inhibitor Anticomplement factor D AMD Phase II
Factor B inhibitor TA106/anti-complement factor B AMD Preclinical
C5 inhibitors
Eculizumab
PNH
Side eﬀects: headache,
thrombocytopenia, gastrointestinal
complaints and infections.
Before use: vaccination against
meningococcal infection.
In clinical use, FDA
approved.
Various other diseases, for example,
kidney transplants, HUS, AMD.
Phase I
Pexelizumab Phase III study failed
Mubodina HUS Preclinical
Ergidina Ischemia/reperfusion injury Preclinical
ARC 1905 AMD Phase I
C5a inhibitor
PMX 53 and several other
compounds
AMD Phase II study discontinued
Osteoarthritis Phase I
Targeted complement inhibitors
Targeted
(CR2 mediated) complement
inhibitors
Chronic glomerulonephritis Phase I
HAE: hereditary angioedema; AMD: acute macular degeneration; HUS: haemolytic uraemic syndrome; PNH: paroxysmal nocturnal haematuria.
AP activation and binding to complement inhibitor C4b-
binding protein avoids CP activation. However, Borreliae
appear to have specific eﬀects on the complement cascade
which finally do not result in a decrease of the inflammatory
response. Adversely, aggravated inflammation is observed
during borrelial infection. The scabies mite Sarcoptes scabiei,
which can cause a parasitic infestation of the skin, expresses
serine protease inhibitors in their gut and faeces that interfere
with all three complement activation pathways leading to
an overall complement inhibition [60]. Probably, the scabies
protect themselves by excreting complement inhibitors.
3.4. Complement Inhibitors in Medicinal Plant Extracts.
Although plants lack genes encoding complement molecules,
complement inhibitors have been found in extracts from
various species of plants and trees (Table 2). Here, we
will only mention some interesting examples from plants
used in traditional medicine all over the world to treat
(inflammatory) diseases and wounds. Deharo et al. studied
complement inhibiting properties of plant extracts used
by the Tacana ethnic group in Bolivia and found six
new species that produced molecules that inhibited the
classical and alternative pathway [71]. Ferna´ndez et al.
showed complement reducing eﬀects in extracts of five
diﬀerent plants that are traditionally used in Argentina [61].
Hawaiian medicinal plants were investigated by Locher et
al. and Eugenia malaccensis was found to produce molecules
that inhibit the classical pathway, which could explain (in
part) its activity against inflammatory diseases, including
wound healing [80]. Other examples of plants producing
complement inhibitors in Mali are the extracts of the
root of Entada africana, leaves of Trichilia emetica and
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Table 2: An overview of complement inhibitors in extracts from plant species.
Plant L.
Part of plant
(extract)
Mode of action Beneficial eﬀects References
Achyrocline flaccida
(YellowMarcela)
Aerial parts
CP inhibition.
IC50 (CP) = 23.5–88.9μg/mL
Antispasmodic, antipyretic,
antihelmintic, antibacterial, antiviral.
Stimulant, emmenagogue, excitant.
[61]
Aloe vera Leaves
AP activation, resulting in consumption
of C3.
Antibacterial, antifungal, antiparasitic,
antitumor, laxative. Used for
seborrheic dermatitis, radiation
dermatitis, psoriasis vulgaris, genital
herpes, burn wounds, diabetes, HIV
infection, ulcerative colitis, pressure
ulcers, mucositis, aphthous stomatitis,
acne vulgaris, lichen planus, frostbite,
alopecia, systemic lupus
erythematosus, arthritis, tic
douloureux.
[62, 63]
Apeiba tibourbou
(Monkey comb)
Leaves CP and AP inhibition.
Antispasmodic, mucilaginous, and
pectoral properties. Used for
rheumatism.
[64]
Artemisia species
(A. dracunculus, A.
montana, A. princeps, A.
rubripes, A. tripartita)
Leaves
CP inhibition.
IC50 (CP) = 54.3–64.2μg/mL
Used for colic pain, vomiting,
diarrhea, dysmenorrhea.
[65–68]
Ascophyllumnodosum
(Brown seaweed)
Leaves
CP inhibition. Fucoidan binds C1q and
prevents the formation of active C1. It
forms a complex with C4
Anti-inflammatory, antiangiogenic,
anticoagulant, antiadhesive.
[69, 70]
Astroniumurundeuva Stem bark
CP and AP inhibition.
IC50 (CP) = 64 μg/mL
IC50 (AP) = 111 μg/mL
Used for wound healing, bone healing,
inflamed sores, gastric ulcers, uterine
hemorrhages, metrorragias, cervicitis.
[71]
Avicenniamarina
(Evergreen shrub)
Stem bark
CP inhibition.
IC50 (CP) = 23–248 μg/mL
Antitumor, anti-inflammatory,
antiviral. Used for skin diseases,
wound healing, rheumatism,
smallpox, ulcers, malaria.
[72]
Biophytum petersianum
Klotsch
Aerial parts
CP inhibition.
IC50 (CP) ≤2–86 μg/mL
Used for wound healing,
inflammation.
[65, 73]
Boswellia serrata
(Frankincense)
Oleogum
resin
CP inhibition, it inhibits C3 convertase
Antihelminthic, antiseptic,
haemostatic, analgesic, cardiotonic,
diuretic, aphrodisiac, laxative. Used for
Crohn’s disease, ulcerative colitis,
bronchial asthma, rheumatoid
arthritis, osteoarthritis, wound
cleaning, reducing fat, diarrhea,
improving menstruation.
[74, 75]
Bridelia ferruginea Stem bark
CP and AP inhibition. Inhibition of C1
and terminal complex.
Used for rheumatism. [76]
Cochlospermum
vitifolium
(silk cotton tree)
Stem bark
CP and AP inhibition.
IC50 (CP) = 104 μg/mL
IC50 (AP) = 135 μg/mL
Used for diabetes, hepatobiliary and
cardiovascular diseases, hypertension,
pain, kidney diseases, ulcers.
[71, 77]
Croton draco Latex
CP and AP inhibition.
IC50 (CP) = 430–590 μg/mL
IC50 (AP) = 680–930 μg/mL
Antibacterial, antitumor, antiviral.
Used for wound healing,
inflammation.
[78]
Entada africana Roots
CP inhibition.
IC50 (CP) = 75–370 μg/mL
Hepatoprotective, haemostatic,
antipyretic, antiseptic, diuretic,
antigonococci, antisyphilitic,
antiparasitic, abortifacient. Used for
wound healing, malaria, respiratory
diseases, psoriasis, rheumatism,
cataract, dysentery.
[79]
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Plant L.
Part of plant
(extract)
Mode of action Beneficial eﬀects References
Eugenia malaccensis
(Malay rose apple)
Stem bark
CP inhibition: IC50 (CP) = 12 μg/mL
AP was activated: 50 % activation at
6 μg/mL
Used for general debility, sore throat,
wound healing, candidiasis, venereal
diseases, tuberculosis, digestive tract
disorders.
[80]
Eupatorium arnottianum Aerial parts
CP and AP inhibition.
IC50 (CP) = 5.0–155.9 μg/mL
IC50 (AP) = 101.3 μg/mL
Antimicrobial, antiviral,
antinociceptive. Used for gastric pain.
[61]
Eupatorium buniifolium Aerial parts
CP inhibition.
IC50 (CP) = 44.1–66.7 μg/mL
Hepatoprotective, antiviral, antiseptic. [61]
Euterpe precatoria
(Ac¸ai)
Roots
CP and AP inhibition.
IC50 (CP) = 105 μg/mL
IC50 (AP) = 147 μg/mL
Antioxidant. Used for muscular pain,
sciatic pain, liver and kidney diseases,
wound healing, skin ulcers, edema,
inflammatory diseases.
[71]
Glycine max
(Soyabean)
Seeds
In vitro it inhibits synthesis and secretion
of C2 and C4 by guinea pig peritoneal
macrophages
Antioxidant, anti-inflammatory,
antitumor, antioestrogenic, antifungal,
insulinotropic. Used for
atherosclerosis, skin whitening,
[81, 82]
Glycyrrhiza
glabra (Licorice)
Roots and
rhizomes
Glycyrrhizin binds to C3a and C3. It
induces conformational changes in C3
and it inhibits CP at the level of C2.
Anti-inflammatory, antiviral,
antimicrobial, antioxidative,
antitumor, immunomodulatory,
hepatoprotective, cardioprotective,
diuretic, anabolic, laxative,
contraceptive. Used for wound
healing, cystitis, diabetes, cough,
stomachache, tuberculosis,
nefrolitiasis, lung ailment, Addison’s
disease, gastric ulcers, improvement of
voice, improvement of male sexual
function.
[83, 84]
Isopyrum thalictroides
Roots and
aerial parts
CP inhibition. Ca2+ and Mg2+ dependent
complement inhibition. It inhibits C1
formation.
Rheumatism, neuralgia, silicosis,
malaria.
[81]
Jatropha
multifida/Jatropha
curcas (Coral plant)
Latex
CP inhibition, mediated by Ca2+
depletion
Used for infected wounds. [81, 85]
Lithraea molleoides Leaves
CP inhibition.
IC50 (CP) = 59.0–86.1 μg/mL
Anti-arthritic, haemostatic, diuretic,
tonic. Used for respiratory diseases. It
causes allergic contact dermatitis.
[61]
Opilia celtidifolia Leaves
CP inhibition.
IC50 (CP) = 0.5–29 μg/mL
Haemostatic. Used for wound healing. [73]
Piper kadsura
(Japanese pepper)
Stem bark
It inhibits C5a-induced chemotaxis and
decreased the stimulated production of
TNF-α and IL-1-β
Asthma, rheumatic arthritis [86]
Phyllanthus sellowianus
Leaves and
stems
CP and AP inhibition.
IC50 (CP) = 11.2–22.0 μg/mL
IC50 (AP) = 280.6 μg/mL
Hypoglycemic, diuretic, laxative,
antiseptic, antinociceptic. [61, 87]
Rosmarinus
oﬃcinalis/Melissa
oﬃcinalis (Rosemary)
Leaves
CP and AP inhibition. It binds C3 and
inhibits C5 convertase. C5a generation is
decreased. IC50 (CP) = 2 μg/mL
Antispasmodic, choleretic,
hepatoprotective, anti-inflammatory,
antitumor, antioxidant. Used for renal
colic pain, dysmenorrhea, respiratory
disorder (bronchial asthma),
stimulation of hair growth, relaxation
of smooth muscles of trachea and
intestine, peptic ulcers, atherosclerosis,
ischaemic heart disease, cataract,
improvement of sperm motility.
[81, 88, 89]
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Plant L.
Part of plant
(extract)
Mode of action Beneficial eﬀects References
Trichilia emetica
(Natal mahogany)
Leaves
CP inhibition.
IC50 (CP) ≤15–62.5 μg/mL
Antipyretic, antiepileptic,
antigonococci, antisyphilitic,
anti-parasitic. Used for wound healing,
dysmenorrhea, asthma, vomiting,
hepatitis, improvement of fertility
(women), gastric diseases, malaria,
hypertension, rheumatism, lumbago.
[90]
Triplaris americana
(Ant tree)
Stem bark
CP and AP inhibition.
IC50 (CP) = 74 μg/mL
IC50 (AP) = 89 μg/mL
Antioxidant, parturifacient. Used for
metrorragias, diarrhea, stomachache,
intestinal worms, leishmaniasis, skin
ulcers.
[71]
Ulex europaeus
(Common gorse)
Seeds
It attenuates MBL binding on human
endothelial cells and inhibited C3
deposition. The dcreased LP activation
resulted in less complement-dependent
neutrophil chemotaxis.
IC50 = 10 pmol/L
None. [91]
Uncaria tomentosa
(Cat’s claw)
Stem bark
CP and AP inhibition.
IC50 (CP) = 124 μg/mL
IC50 (AP) = 151 μg/mL
Anti-inflammatory, antiviral,
immunostimulating, antimutagenic,
antioxidant. Used for gastritis, dermic
and urogenital inflammations, asthma,
rheumatism, irregular menstruation,
digestive, liver and kidney diseases,
adjuvant therapy for breast cancer.
[71, 92]
CP: classical pathway; AP: alternative pathway; LP: Lectin Pathway; IC50: concentration required for 50% complement inhibition. Most of these complement
inhibition tests were performed using complement haemolytic activity assays. Compounds in these plant species inhibiting the complement system are; for
example; flavonoids, glucosides, polysaccharides, terpenes, iridoids, polymers, peptides, alkaloids, and oils [81]. Other complement inhibitors from plants
are found in Acanthus ilicifolius[72], Atractylodes lancea [73], Angelica acutiloba [73, 81, 93], Azadirachta indica [81], Bupleurum falcatum [94], Cedrela
lilloi [81], Centaurium spicatum [81], Cochlospermum tinctorium [95], Crataegus sinaica [81], Crataeva nurvala [81], Curcuma longa [96], Dendropanax
morbifera Leveille [97],Glinus oppositifolius [79], Juglans mandshurica [98], Ligularia taquetii [99], Litsea japonica [100], Ligustrum vulgare [81], Lithospermum
euchromum [81], Magnolia fargesii [101], Melothria maderaspatana [102], Morinda morindoides [81], Olea europaea [81], Osbeckia octandra [102], Ocimum
basilicum [66], Osbeckia aspera [81], Panax ginseng [103], Paulownia tomentosa var. tomentosa [104], Persicaria lapathifolia [81], Petasites hybridus [81],
Phillyrea latifolia [81], Phyllanthus debilis [102], Picria fel-terrae [105], Plantago major [81], Sorghum bicolor [106], Terminalia amazonia [71], Thymus vulgaris
[66], Tinospora cordifolia [81], Trichilia elegans [90], Trichilia glabra [81, 90], Vernonia Kotschyana [72, 73, 95], Wedelia chinensis [107], and Woodfoidra
fruticosa [81].
Opilia celtidifolia, and water extract of the aerial parts of
Biophytum petersianum Klotsch, which are traditionally used
in Mali to cure wounds and to reduce fever [65, 73,
79, 90]. Natural latex from rubber trees also has wound
healing properties and extracts of Jatropha multifida and
Croton Draco were able to inhibit the classical pathway
of complement activation [78, 85]. Plant extracts interfere
with the complement system at diﬀerent stages of the
cascade (Table 2). Bridelia ferruginea, Isopyrum thalictroides,
and Ascophyllum nodosum inhibit C1 formation and the
latter one also forms a complex with C4 [69, 70, 76, 81].
Glycyrrhiza glabra reduces C2 [83, 84] and Glycine max
inhibits synthesis of C2 and C4 [81, 82]. C3 is aﬀected by
Aloe vera, Boswellia serrata, Glycyrrhiza glabra, Rosmarinus
oﬃcinalis, and Ulex europaeus [62, 63, 74, 75, 81, 83, 84,
88, 89, 91]. Production of anaphylatoxin C5a is decreased
by Piper kadsura and Rosmarinus oﬃcinalis [81, 86, 88,
89]. Future research should focus on the purification and
characterization of the eﬀective substances in plants and
the specificity and exact mechanisms of action of these
compounds.
4. Discussion and Future Research
Complement serves as a rapid and eﬃcient immune surveil-
lance system to control infection and tissue injury. The
complement system regulates the clearance of necrotic and
apoptotic cells, inflammation, and tissue regeneration. How-
ever, elevated levels of C3, C3a, C3d, and MAC have been
reported in chronic wounds and burn or traumatic wounds
[27–32], indicating that uncontrolled complement activation
occurs in such wounds. In addition, studies in animals
with deficiencies in complement components and in patients
treated with complement inhibiting agents confirmed the
importance of controlling the complement system in wound
healing and fibrosis [12–18, 108]. Specific inhibitors can
balance the functional activities of the complement system
and progress the healing process, as shown in patients with
burn wounds treated with a C1 inhibitor or a soluble human
recombinant complement receptor type 1 as well as in C4-
deficient mice [15–18]. Thus, attenuation of complement
activation by therapeutic agents may improve the healing
process in chronic wounds.
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Figure 2: Dose-dependent eﬀect of fresh collected maggot ES on
activation of the classical pathway (white bars), the alternative
pathway (grey bars), and the lectin pathway (black bars) in normal
human sera. The complement activation in four diﬀerent sera
was determined with the enzyme immunoassays from Wieslab
(EuroDiagnostica BV, Arnhem, The Netherlands) according to
manufacturer’s instructions. The percentages inhibition was calcu-
lated using the values in the sera without maggot ES as 0%. The
results are means and SD of four independent experiments.
However, several challenges have to be overcome before
complement inhibitors can be included in the therapeutic
arsenal for wound care. For example, complement inhibitors
should act locally at the site of inflammation or injury, thus
avoiding the adverse eﬀects of a systemic complement block-
ade, that is, infection and impaired wound healing [109]. For
this purpose, current research focuses on the development
of strategies to target the complement inhibitor to the sites
of complement activation, regardless of the location. In this
connection, a Phase I study has recently been performed
in which various complement inhibitors were linked to a
targeting moiety consisting of complement receptor 2 (CR2)
[110]. CR2 binds long-lived C3 fragments and thereby acts
to target the attached complement inhibitor to the site of
inflammation/injury. In agreement, experiments in mice
showed an increased potency and prolonged local presence
of such complement inhibitors, while leaving the systemic
complement activation intact [42]. No increased risk of
infection or sepsis was observed in these animals. Another
example is perfusion of cadaveric kidneys during the transfer
from the donor to the recipient with mirococept which is a
peptidyl derivative of sCR1 engineered to stick to the organ
during this process [40].
One more issue pertains to the contribution of local
production and functional activities of complement com-
ponents and their regulators. Although the liver is the
main source of complement components, the production of
several complement components, for example, properdin,
C1, C3, and C7, at sites of inflammation/injury should
be studied in more detail. Furthermore, good aﬃnity of
the complement inhibitors for the target and selectivity are
important factors to consider in anti-complement therapies.
Moreover, the complement inhibitor must have a long half-
life.
The choice of the complement inhibitor depends on
the role the complement has in the disease. C5 inhibitors
are preferred for the treatment of diseases in which C5a
and MAC play a major role, for example, in HUS and
in patients suﬀering from an infection with the EHEC
bacterium [111]. Cleavage of C5 generates C5a, a major
inflammatory mediator, and C5b initiating the formation
of MAC. These two factors are the key eﬀectors of the
complement system responsible for both wound repair and
persistent inflammation [112]. Obviously, the eﬀects of
complement inhibitors also depend on the stage of the
disease in the patients. In this context, it is interesting to
see that the C5-inhibitor eculizumab is eﬃcacious for PNH
and HUS [36], while pexelizumab having the same mode of
action as eculizumab was ineﬀective in patients undergoing
percutaneous coronary intervention after myocardial infarc-
tion [37]. This failure of pexelizumab could be due to late
administration of the antibody after ischemia-reperfusion
and/or diﬀerences in their half-lifes, that is, eculizumab
has an average half-life of 272 hours and pexelizumab of
7–14 hours. In agreement, administration of pexelizumab
before coronary arterial bypass grafting did have a beneficial
outcome [37]. Of note, it was found that in vitro both C5a
and MAC were both blocked by these antibodies directed
against C5 while in vivo C5a activity (but not MAC)
was blocked. Finally, there are concerns about the clinical
use of nonspecific complement inhibiting agents as these
agents may have adverse consequences for patients, such as
(recurrent) infections [109].
Although there are a lot of challenges to overcome, there
are some promising complement inhibitors. For example,
the pathway-independent inhibitor compstatin is extensively
tested in clinical studies in patients suﬀering from acute and
chronic inflammatory conditions. The results up to date are
successful [36]. Furthermore, a novel complement inhibitor
could be based on the active component(s) in ES of Lucilia
sericata larvae as ES reduce all three complement activating
pathways in normal and immune-activated human sera in a
dose-dependent manner [53]. Moreover, it should be kept in
mind that these maggots are already in clinical use for many
years without any side eﬀects reported in the literature nor
in our own clinical experience with this therapy over the past
ten years [44, 45].
Another important question that remains unanswered
is how much the complement system can be attenuated
without the risk of loss of protection. Based on our finding
that a single maggot produces approximately 2 μg of ES per
hour [53, 113] and assuming that 125maggots are applied on
a wound surface (of about 25 square centimeter), the amount
of ES in the wound (per hour) is 250 μg, which correlates
with a 50% complement reduction (Figure 2). Thus, we
believe that reduction of the local complement activity of
about 50% is safe and eﬀective. However, further research is
required before a definitive conclusion can be drawn.
To conclude, well-designed (pre)clinical studies aimed at
understanding the roles of complement in the pathology of
chronic wounds, with the hope of innovative drugs and their
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clinical implementation to promote healing in patients with
chronic wounds, are urgently needed.
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